TabernaDB

2,5-ETHANO-2H-AZOCINO(4,3-B)INDOL-6(3H)-ONE, 4-ETHYLIDENE-1,4,5,7-TETRAHYDRO-, (2R,4E,5S)-
(+)-Conolidine
(+)-ERVATICINE
(2R,4E,5S)-4-Ethylidene-1,4,5,7-tetrahydro-2,5-ethano-2H-azocino[4,3-b]indol-6(3H)-one
Ervaticine
2,5-Ethano-2H-azocino[4,3-b]indol-6(3H)-one, 4-ethylidene-1,4,5,7-tetrahydro-, (2R,4E,5S)-
SCHEMBL10073828
Conolidine
DTXSID401126453
100414-81-1
Q15410923
(1R,13S,14E)-14-ethylidene-1,10- diazatetracyclo(11.2.2.0(3,11).0{4,9})heptadeca-3(11),4,6,8-tetraen-12-one
UNII-WJ97DL8YCB
WJ97DL8YCB

Canonical SMILES

C/C=C\1/CN2CC[C@@H]1C(=O)C3=C(C2)C4=CC=CC=C4N3
InChI

InChI=1S/C17H18N2O/c1-2-11-9-19-8-7-12(11)17(20)16-14(10-19)13-5-3-4-6-15(13)18-16/h2-6,12,18H,7-10H2,1H3/b11-2-/t12-/m0/s1

Molecule Class: Alkaloids
TPSA: 36.1
#RotBonds: 0
MW: 266.34399999999994
HBD: 1
HBA: 2
logP: 3.1324000000000014
Chemical Formula: C₁₇H₁₈N₂O

Species	Place of Collection	NCBI Taxonomy	Voucher Specimen
T. bufalina	China	403123	Cai20170220
T. divaricata	China, Japan, Thailand, Bangladesh, Vienna	52861	BBP0671

- PubChem CID: 51051652
- CAS RN: 100414-81-1

Alkaloids isolated from Tabernaemontana bufalina display xanthine oxidase inhibitory activity. Phytochemistry, 2019 (PMID 31302343).
Biologically active ibogan and vallesamine derivatives from Tabernaemontana divaricata. Chem Biodivers, 2004 (PMID 17191876).
Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain. Nat Chem, 2011 (PMID 21602859).
Virtual Screening of compounds from Tabernaemontana divaricata for potential anti-bacterial activity. Bioinformation, 2014 (PMID 24748755).

Antibacterial
Xanthine oxidase inhibitory
Analgesic
Inhibitory
Cytotoxicity

N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Property	Model Name	Predicted Value

Absorption	Caco-2 (logPaap)	-4.76
	Human Oral Bioavailability 20%	Bioavailable
	Human Intestinal Absorption	Absorbed
	Madin-Darby Canine Kidney	-4.76
	Human Oral Bioavailability 50%	Bioavailable
	P-Glycoprotein Inhibitor	Non-Inhibitor
	P-Glycoprotein Substrate	Non-Substrate
	Skin Permeability	-2.31

Distribution	Blood-Brain Barrier (Central Nervous System)	-2.43
	Blood-Brain Barrier	Penetrable
	Fraction Unbound (Human)	0.69
	Plasma Protein Binding	56.01
	Steady State Volume of Distribution	3.74

Metabolism	Breast Cancer Resistance Protein	Non-Inhibitor
	CYP 1A2 Inhibitor	Inhibitor
	CYP 1A2 substrate	Substrate
	CYP 2C19 Inhibitor	Non-Inhibitor
	CYP 2C19 substrate	Substrate
	CYP 2C9 Inhibitor	Non-Inhibitor
	CYP 2C9 Substrate	Substrate
	CYP 2D6 Inhibitor	Inhibitor
	CYP 2D6 Substrate	Substrate
	CYP 3A4 Inhibitor	Non-Inhibitor
	CYP 3A4 Substrate	Substrate
	OATP1B1	Non-Inhibitor
	OATP1B3	Non-Inhibitor

Excretion	Clearance	10.8
	Organic Cation Transporter 2	Inhibitor
	Half-Life of Drug	Half-Life < 3hs

Toxicity	AMES Mutagenesis	Toxic
	Avian	Safe
	Bee	Safe
	Bioconcentration Factor	0.31
	Biodegradation	Safe
	Carcinogenesis	Safe
	Crustacean	Toxic
	Liver Injury I	Safe
	Eye Corrosion	Safe
	Eye irritation	Safe
	Maximum Tolerated Dose	-0.94
	Liver Injury II	Toxic
	hERG Blockers	Safe
	Daphnia Maga	4.88
	Micronucleos	Toxic
	NR-AhR	Toxic
	NR-AR	Safe
	NR-AR-LBD	Safe
	NR-Aromatase	Safe
	NR-ER	Safe
	NR-ER-LBD	Safe
	NR-GR	Safe
	NR-PPAR-gamma	Safe
	NR-TR	Safe
	T. Pyriformis	2.58
	Rat (Acute)	2.82
	Rat (Chronic Oral)	2.15
	Fathead Minnow	4.47
	Respiratory Disease	Toxic
	Skin Sensitisation	Toxic
	SR-ATAD5	Safe
	SR-ARE	Safe
	SR-HSE	Safe
	SR-MMP	Safe
	SR-p53	Safe

General Properties	Boiling Point	390.07
	Hydration Free Energy	-8.15
	Log(D) at pH=7.4	2.02
	Log(P)	2.63
	Log S	-3.54
	Log(Vapor Pressure)	-8.32
	Melting Point	209.06
	pKa Acid	7.33
	pKa Basic	7.15

Conolidine